Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02131064 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
A Phase 3 study of Breast Neoplasms, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 444
- Enrollment target
- 20
- Study locations
NCT02131064 is a Phase 3 study of Breast Neoplasms that has completed, run by Hoffmann-La Roche. The registered enrollment target is 444 participants, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT02131064, a Phase 3 study of Breast Neoplasms, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 444 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, multicenter, open-label, two-arm study in treatment-naive participants with operable, locally advanced, or inflammatory, centrally-assessed HER2-positive early breast cancer (EBC) whose primary tumors were greater than or equal to (\>/=) 2 centimeters (cm). The study was designed to evaluate the efficacy and safety of trastuzumab emtansine + pertuzumab (experimental arm; T-DM1 + P) versus chemotherapy, trastuzumab + pertuzumab (control arm; TCH + P). The study comprised a neoadjuvant treatment period, followed by surgery, and an adjuvant treatment period. Treatment can be stopped due to disease recurrence, unacceptable toxicity, withdrawal of consent, or study termination.
Conditions Studied
Interventions
- DRUG Trastuzumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Pertuzumab
- DRUG Trastuzumab Emtansine
Study Locations (20)
California
- St. Jude Heritage Healthcare; Virgiia K.Crosson Can Ctr - Fullerton
- Cancer Care Assoc Med Group - Los Angeles
- Coastal Integrative Cancer Care - San Luis Obispo
- Central Coast Medical Oncology - Santa Maria
- UCLA Hematology/Oncology - Santa Monica
Other
- UZ Antwerpen - Edegem
- UZ Leuven Gasthuisberg - Leuven
- Clinique Saint-Joseph - Liège
- Clinique Ste-Elisabeth, Pharmacie - Namur
Florida
- Memorial Cancer Institute - Hollywood
- Md Anderson Cancer Center Orlando - Orlando
New York
- ProHEALTH Care Associates LLP - Lake Success
- Montefiore Medical Center - The Bronx
North Carolina
- Hope A Women's Cancer Center - Asheville
- Levine Cancer Institute - Charlotte
Maine
- New England Cancer Specialists - Scarborough
Nevada
- Comprehensive Cancer Centers of Nevada - Henderson - Henderson
South Carolina
- Roper Bon Secours St. Francis Cancer Center - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 444 participants |
| Start Date | 2014-06-25 |
| Est. Completion | 2018-05-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02131064
The ClinicalTrials.gov registry entry for NCT02131064 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 444 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 564-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (21% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Trastuzumab is the first listed.
NCT02131064 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Other, Florida.
Frequently Asked Questions
What is clinical trial NCT02131064 about?
NCT02131064 is a clinical study titled "A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer". This is a randomized, multicenter, open-label, two-arm study in treatment-naive participants with operable, locally advanced, or inflammatory, centrally-assessed HER2-positive early breast cancer (EBC) whose primary tumors were greater than or equal to (\>/=) 2 centimeters (cm). The study was design...
What is the current status of trial NCT02131064?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 444 participants. The study started on 2014-06-25. Estimated completion is 2018-05-29.
What conditions does trial NCT02131064 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT02131064?
The interventions under investigation include: Trastuzumab (DRUG), Carboplatin (DRUG), Docetaxel (DRUG), Pertuzumab (DRUG), Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT02131064?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02131064 being conducted?
This trial has 20 study locations across California, Florida, Maine, Nevada, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RECRUITING · Phase 3
-
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
-
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RECRUITING · Phase 3
-
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
RECRUITING · Phase 3
-
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.